Combined Inhibition of Polo-like kinase 1 (Plk1) and Microtubule Polymerization for the Treatment of Cancer

An effective amount of one or more microtubule polymerization inhibitors is administered in combination with one or more polo-like kinase (Plk) inhibitors for treating cancer. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree, than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers are also provided.